spironolactone has been researched along with Androgen-Independent Prostatic Cancer in 4 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone treatment was maintained as it was considered beneficial due to the cardiac condition." | 1.72 | Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients. ( Collado-Borrell, R; Escudero-Vilaplana, V; Herranz, A; López-López, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Sanjurjo, M; Somoza-Fernández, B; Vicente-Valor, J; Villanueva-Bueno, C, 2022) |
| "Eplerenone is a nonsteroidal mineralocorticoid antagonist demonstrated to abrogate mineralocorticoid excess." | 1.46 | Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. ( Agarwal, N; Alex, A; Bailey, E; Batten, J; Boucher, K; Gaston, D; Gill, D; Gupta, S; Hahn, A; Stenehjem, D, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vicente-Valor, J | 1 |
| Escudero-Vilaplana, V | 1 |
| Collado-Borrell, R | 1 |
| López-López, C | 1 |
| Villanueva-Bueno, C | 1 |
| Revuelta-Herrero, JL | 1 |
| Ruiz-Briones, P | 1 |
| Somoza-Fernández, B | 1 |
| Herranz, A | 1 |
| Sanjurjo, M | 1 |
| Dhondt, B | 1 |
| Buelens, S | 1 |
| Van Besien, J | 1 |
| Beysens, M | 1 |
| De Bleser, E | 1 |
| Ost, P | 1 |
| Lumen, N | 1 |
| Flynn, T | 1 |
| Guancial, EA | 1 |
| Kilari, M | 1 |
| Kilari, D | 1 |
| Gill, D | 1 |
| Gaston, D | 1 |
| Bailey, E | 1 |
| Hahn, A | 1 |
| Gupta, S | 1 |
| Batten, J | 1 |
| Alex, A | 1 |
| Boucher, K | 1 |
| Stenehjem, D | 1 |
| Agarwal, N | 1 |
4 other studies available for spironolactone and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplas | 2022 |
Abiraterone and spironolactone in prostate cancer: a combination to avoid.
Topics: Abiraterone Acetate; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Contraindications, Dr | 2019 |
Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer.
Topics: Abiraterone Acetate; Benzamides; Drug Antagonism; Humans; Male; Middle Aged; Neoplasm Metastasis; Ni | 2017 |
Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.
Topics: Abiraterone Acetate; Aged; Antineoplastic Combined Chemotherapy Protocols; Eplerenone; Humans; Male; | 2017 |